Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights
Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights
Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights
Download
